[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"sexual-disfunction\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:sexual-disfunction":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,56],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":35,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":44,"lastUpdatePostDateStruct":45,"startDateStruct":48,"completionDateStruct":50,"leadSponsor":52,"locationsCount":55},"100607843","sexual-dysfunction-in-women-with-multiple-sclerosis-ms-100607843",false,"NCT07193823","Sexual Dysfunction in Women With Multiple Sclerosis (MS)","Sexual Dysfunction Prevalence and Its Relationship With Various Factors in Women With Multiple Sclerosis","MS","Inclusion Criteria:\n\n* Female patients aged 25-50 years\n* Literate and able to comprehend written and spoken instructions\n* Diagnosed with relapsing-remitting form of multiple sclerosis\n* Having a continuous\u002Fregular sexual partner\n* Expanded Disability Status Scale (EDSS) score ≤ 5\n* At least 3 months since the last relapse\n* Sexually active within the past 3 months\n* Spasticity level \\\u003C grade 2 according to the Modified Ashworth Scale\n\nExclusion Criteria:\n\n* Pregnancy\n* Illiteracy or inability to understand spoken or written instructions\n* Absence of a continuous\u002Fregular sexual partner\n* Expanded Disability Status Scale (EDSS) score \\> 5\n* Not sexually active within the past 3 months\n* Spasticity level ≥ grade 2 according to the Modified Ashworth Scale","FEMALE","25 Years","50 Years",{"count":21,"type":22},140,"ESTIMATED","OBSERVATIONAL","Sexual dysfunction in women with multiple sclerosis (MS) is an important yet often overlooked problem. The primary objective of this study is to investigate the prevalence of sexual dysfunction in female patients diagnosed with MS. The secondary objective is to evaluate the relationship between sexual dysfunction and fatigue, depression, anxiety, overactive bladder symptoms, and cognitive dysfunction.\n\nFor this purpose, the following validated instruments will be used: the Female Sexual Function Index (FSFI) to assess sexual dysfunction, the Brief International Cognitive Assessment for MS (BICAMS) to evaluate cognitive function, the Hospital Anxiety and Depression Scale (HADS) to assess depression and anxiety, the Fatigue Severity Scale (FSS) to measure fatigue, and the Overactive Bladder Questionnaire (OAB-V8) to evaluate overactive bladder symptoms.",[26,27,28,29,30,31,32,33,34],"Multiple Sclerosis","Multiple Sclerosis (MS) - Relapsing-remitting","Fatigue in Multiple Sclerosis","Sexual Disfunction","Cognitive Dysfunction","Depression","Anxiety","Overactive Bladder","Fatigue",[36,37,38,39,40,41,42],"multiple sclerosis","sexual dysfunction","cognitive dysfunction","depression","anxiety","overactive bladder","fatigue","RECRUITING","2025-09-22",{"date":46,"type":47},"2025-09-26","ACTUAL",{"date":49,"type":47},"2024-07-16",{"date":51,"type":22},"2025-11",{"name":53,"class":54},"Ege University","OTHER",1,{"id":57,"slug":58,"hasResults":11,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":4,"eligibilityCriteria":62,"healthyVolunteers":11,"sex":17,"minAge":63,"maxAge":64,"enrollmentInfo":65,"targetDuration":4,"studyType":67,"phases":68,"briefSummary":70,"conditions":71,"keywords":78,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":55},"100579772","treatment-of-vulvo-vaginal-atrophy-vva-using-vaginal-dilator-in-addition-to-usual-treatment-100579772","NCT06828640","Treatment of Vulvo-vaginal Atrophy (VVA) Using Vaginal Dilator in Addition to Usual Treatment","Treatment of Vulvo-vaginal Atrophy (VVA) Using Vaginal Dilator in Addition to Usual Treatment : a Randomized Control Trial","Inclusion Criteria:\n\n* Peri- or postmenopausal women suffering from vulvovaginal atrophy (VVA)\n* Breast cancer survivors with VVA symptoms\n* Understand the study, be willing to participate, and sign an informed consent form.\n* The use of estrogen\u002Fprogestogen-based products (vaginal, oral, pellets, transdermal, etc.) is permitted but must be documented (this will be considered during randomization).\n\nExclusion Criteria:\n\n* Undiagnosed abnormal genital bleeding.\n* Administration of any investigational drug within 30 days prior to the screening visit.\n* Presence of a serious medical condition, neurological disorder, or significant comorbidities.\n* Other gynecological malignancies.\n* Recent vaginal surgery.\n* Clinically significant prolapse (POP-Q ≤ 2).\n* Current urinary tract or vaginal infection, or recent sexually transmitted infection.\n* Individuals with disabilities unable to communicate.\n* Women eligible for the study but unwilling to participate.","18 Years","85 Years",{"count":66,"type":22},160,"INTERVENTIONAL",[69],"NA","This is a randomized, controlled trial aiming to evaluate the effectiveness of adding vaginal dilators to the treatment of vulvovaginal atrophy.\n\nStudy Population:\n\nPeri- and postmenopausal women with VVA, including breast cancer survivors.\n\nDesign: Monocentric pilot RCT evaluating SoC (MHT, lubricants, moisturizers) (control group) to SoC + vaginal dilators (test group).\n\nVaginal Dilator : A silicone medical device will be used for gradual stretching progression. The kit includes dilators of progressively larger sizes.\n\nProcedures: Assessments at baseline, at 4 \\& 12 weeks\n\nMeasures : Vulvo Vaginal Atrophy severity , dyspareunia, Vaginal Health Index Score, Female Sexual Fonction Index, and Visual Analogue Scale (for vaginal dryness, vaginal and\u002For vulvar irritation\u002Fitching, and pain during sexual intercourse).\n\nStatistical Analysis:\n\nDifferences at baseline, 4 weeks, and 12 weeks will be tested using:\n\nTwo-sample t-test Mann-Whitney test\n\nStatistical Power:\n\nAssuming a 20% improvement in Group 1 and 40% in Group 2, with:\n\np \\\u003C 0.05 (type I error) 80% power (type II error), 160 patients needed across both groups.\n\nSoC = Standard of care RCT = Randimized control trial MHT = Menopausal hormonal therapy",[72,73,74,75,76,29,77],"Vulvo Vaginal Atrophy","Genitourinary Syndrome of Menopause (GSM)","Vaginal Atrophy in Breast Cancer Patients","Vaginal Atrophy Patients With GSM","Treatment","Dyspareunia (Female)",[79,80,81,82],"Vulvo vaginal atrophy","vaginal dilators","Genitourinary syndrome of menopause","treatment","2025-02-11",{"date":85,"type":47},"2025-02-14",{"date":87,"type":47},"2024-10-16",{"date":89,"type":22},"2025-10",{"name":91,"class":54},"Centre Hospitalier Universitaire Saint Pierre"]